Alain Delforge
Overview
Explore the profile of Alain Delforge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
541
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Padalko E, Colenbie L, Delforge A, Ectors N, Guns J, Imbert R, et al.
Cell Tissue Bank
. 2023 Aug;
25(2):509-520.
PMID: 37624485
With the present paper, the Working Group on Cells, Tissues and Organs and other experts of the Superior Health Council of Belgium aimed to provide stakeholders in material of human...
2.
Pirnay J, Baudoux E, Cornu O, Delforge A, Delloye C, Guns J, et al.
EMBO Rep
. 2015 Apr;
16(5):557-62.
PMID: 25851645
No abstract available.
3.
Servais S, Baudoux E, Brichard B, Bron D, Debruyn C, De Hemptinne D, et al.
Haematologica
. 2014 Sep;
100(1):e32-4.
PMID: 25261093
No abstract available.
4.
De Bruyn C, Najar M, Raicevic G, Meuleman N, Pieters K, Stamatopoulos B, et al.
Stem Cells Dev
. 2010 Oct;
20(3):547-57.
PMID: 20923277
The co-infusion of mesenchymal stromal cells (MSCs) with hematopoietic stem cells could improve the hematopoietic engraftment after cord blood transplant. Adult bone marrow is the major source of MSCs for...
5.
Stamatopoulos B, Meuleman N, De Bruyn C, Delforge A, Bron D, Lagneaux L
Haematologica
. 2010 Feb;
95(7):1136-43.
PMID: 20145270
Background: Chronic lymphocytic leukemia is a neoplastic disorder that arises largely as a result of defective apoptosis leading to chemoresistance. Stromal cell-derived factor-1 and its receptor, CXCR4, have been shown...
6.
Tondreau T, Meuleman N, Stamatopoulos B, De Bruyn C, Delforge A, Dejeneffe M, et al.
Cytotherapy
. 2009 Jun;
11(5):559-69.
PMID: 19551542
Background Aims: The transmigratory capacity of bone marrow (BM) mesenchymal stromal cells (MSC) through the endothelial cell barrier into various tissues and their differentiation potential makes them ideal candidates for...
7.
Meuleman N, Tondreau T, Ahmad I, Kwan J, Crokaert F, Delforge A, et al.
Stem Cells Dev
. 2009 Mar;
18(9):1247-52.
PMID: 19309241
Mesenchymal stromal cells (MSCs) are important in the support of hematopoiesis. In this pilot study, we evaluated the safety and efficiency of donor-expanded MSC infusion after allogeneic hematopoietic stem cell...
8.
Tondreau T, Dejeneffe M, Meuleman N, Stamatopoulos B, Delforge A, Martiat P, et al.
BMC Genomics
. 2008 Apr;
9:166.
PMID: 18405367
Background: Neuronal tissue has limited potential to self-renew or repair after neurological diseases. Cellular therapies using stem cells are promising approaches for the treatment of neurological diseases. However, the clinical...
9.
Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, et al.
Exp Hematol
. 2007 Aug;
35(10):1527-37.
PMID: 17697742
Objective: Chronic lymphocytic leukemia (CLL) cells develop chemoresistance over time associated with defects in apoptosis pathway. Novel treatment strategies are required to overcome resistance of cells to commonly used agents....
10.
Meuleman N, Tondreau T, Delforge A, Dejeneffe M, Massy M, Libertalis M, et al.
Eur J Haematol
. 2006 Mar;
76(4):309-16.
PMID: 16519702
The expansion of mesenchymal stem cells (MSCs) strongly depends on the culture conditions and requires medium supplemented with 10-20% fetal calf serum (FCS) to generate relevant numbers of cells. However,...